HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Granulocyte microvesicles with a high plasmin generation capacity promote clot lysis and improve outcome in septic shock.

Abstract
Microvesicles (MVs) have previously been shown to exert profibrinolytic capacity, which is increased in patients with septic shock (SS) with a favorable outcome. We, therefore, hypothesized that the plasmin generation capacity (PGC) could confer to MVs a protective effect supported by their capacity to lyse a thrombus, and we investigated the mechanisms involved. Using an MV-PGC kinetic assay, ELISA, and flow cytometry, we found that granulocyte MVs (Gran-MVs) from SS patients display a heterogeneous PGC profile driven by the uPA (urokinase)/uPAR system. In vitro, these MVs lyse a thrombus according to their MV-PGC levels in a uPA/uPAR-dependent manner, as shown in a fluorescent clot lysis test and a lysis front retraction assay. Fibrinolytic activators conveyed by MVs contribute to approximately 30% of the plasma plasminogenolytic capacity of SS patients. In a murine model of SS, the injection of high PGC Gran-MVs significantly improved mouse survival and reduced the number of thrombi in vital organs. This was associated with a modification of the mouse coagulation and fibrinolysis properties toward a more fibrinolytic profile. Interestingly, mouse survival was not improved when soluble uPA was injected. Finally, using a multiplex array on plasma from SS patients, we found that neutrophil elastase correlates with the effect of high-PGC-capacity plasma and modulates the Gran-MV plasmin generation capacity by cleaving uPA-PAI-1 complexes. In conclusion, we show that the high PGC level displayed by Gran-MVs reduces thrombus formation and improves survival, conferring to Gran-MVs a protective role in a murine model of sepsis.
AuthorsSylvie Cointe, Loris Vallier, Pierre Esnault, Mathilde Dacos, Amandine Bonifay, Nicolas Macagno, Karim Harti Souab, Corinne Chareyre, Coralie Judicone, Diane Frankel, Stéphane Robert, Sami Hraiech, Marie-Christine Alessi, Philippe Poncelet, Jacques Albanese, Françoise Dignat-George, Romaric Lacroix
JournalBlood (Blood) Vol. 139 Issue 15 Pg. 2377-2391 (04 14 2022) ISSN: 1528-0020 [Electronic] United States
PMID35026004 (Publication Type: Journal Article)
Copyright© 2022 by The American Society of Hematology.
Chemical References
  • Fibrinolysin
  • Urokinase-Type Plasminogen Activator
Topics
  • Animals
  • Disease Models, Animal
  • Fibrinolysin
  • Fibrinolysis
  • Granulocytes
  • Humans
  • Mice
  • Shock, Septic
  • Thrombosis
  • Urokinase-Type Plasminogen Activator

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: